Acute kidney injury following amikacin therapy: a retrospective cohort study
Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)
DOI: 10.1093/jac/dkag188 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 26.05.2026. Verfasst von Iris Zohar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Unit, Edith Wolfson Medical Center, Holon, Israel. Hauptthemen laut MEDLINE: Amikacin, Acute Kidney Injury, Anti-Bacterial Agents. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Objectives
Aminoglycosides are historically considered nephrotoxic, though contemporary once-daily dosing and preferential amikacin use may reduce this risk. We evaluated the incidence and risk factors for acute kidney injury (AKI) among patients receiving amikacin.
Methods
A retrospective cohort study of adult inpatients treated with amikacin between July 2018 and June 2022. Exclusion criteria were treatment <3 or >10 days, baseline eGFR <30 mL/min/1.73 m2, or insufficient renal follow-up. AKI was defined by KDIGO criteria. Charts of patients meeting AKI criteria were reviewed to assess likely aetiology. Multivariate logistic regression identified independent predictors.
Results
Of 974 courses, 608 met the inclusion criteria. Patients had a median age of 81.0 years, 52.5% were female and the median baseline eGFR was 67.1 mL/min/1.73 m2. AKI occurred in 48 patients (7.9%), with KDIGO stage 2–3 in 14 (2.3%). Aetiologies included prerenal azotaemia (21%), shock/sepsis (35%), urinary obstruction (17%), contrast exposure (2.1%) and other nephrotoxic medications (2.1%); in 11 patients (22.9% of patients with AKI and 1.8% of the entire cohort), no alternative cause was identified. Multivariate analysis showed independent predictors of AKI were older age, longer interval from admission to treatment and discontinuation due to an infectious indication. Baseline eGFR, daily dose and treatment duration were not associated with AKI.
Conclusions
In this contemporary cohort, we observed a relatively low incidence of AKI, often secondary to, or exacerbated by, other underlying causes. These findings suggest that once-daily amikacin may potentially carry a lower nephrotoxic risk than historically reported. Further studies are warranted to confirm safety in broader patient populations
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Disease Unit, Edith Wolfson Medical Center, Holon, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Neurology Department, Edith Wolfson Medical Center, Holon, Israel.
- Department of Family Medicine, Tel Aviv District, Clalit Health Services, Tel Aviv, Israel.
- Z Software, IBM LTD, Givatayim, Israel.
- Microbiology and Immunology Laboratory, Edith Wolfson Medical Center, Holon, Israel.
ORCID-Profile: Iris Zohar, Yasmin Maor
Zitieren
APA
Zohar, I., Satra-Shenes, B., Melloul, D., Satra-Shenes, O., Pomeranz, A., Abu Hanna, N., Zohar, I., Schwartz, O., Ben David, D., & Maor, Y. (2026). Acute kidney injury following amikacin therapy: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag188
Vancouver
Zohar I, Satra-Shenes B, Melloul D, Satra-Shenes O, Pomeranz A, Abu Hanna N, et al. Acute kidney injury following amikacin therapy: a retrospective cohort study. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag188
BibTeX
@article{Zohar2026,
author = {Zohar, Iris and Satra-Shenes, Baruch and Melloul, Dvir and Satra-Shenes, Orly and Pomeranz, Adam and Abu Hanna, Nidaa and Zohar, Idan and Schwartz, Orna and Ben David, Debby and Maor, Yasmin},
title = {Acute kidney injury following amikacin therapy: a retrospective cohort study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {6},
doi = {10.1093/jac/dkag188}
}
EUVIMED